“…7 Regardless of their complex structure, these lipid-polymer composite nanoparticles (NPs) are synthesized in a simple, single-step fashion, which allows future scale-up in production and cost-effective real-life applications. 1,[7][8][9][10][11][12] It has been established that the functionalization of polymer end groups and subsequent conjugation with targeting motifs such as peptides as a nanoparticle vehicle is a powerful strategy to permit precise drug delivery to the targeted site, while reducing systemic toxicities. 13 The use of the Food and Drug Administration (FDA) approved polymeric biomaterial, polyethylene glycol (PEG), as a surface passivating layer on the nanoparticle prevents aggregation, opsonization, and phagocytosis, and prolongs the systemic circulation time to improve the nanoparticle-based drug delivery system.…”